Cancer Antigen (CA) 125 in the Presence of Human Antimouse Antibodies (HAMA)

TEST: 144733
Test number copied
CPT: 86304
Print Share

Synonyms

  • CA-125 in the Presence of HAMA

Special Instructions

A blocking agent is used to remove interference from HAMA (human antimouse antibodies) in the CA 125 assay. For a complete test description, see Cancer Antigen (CA) 125 [002303].

This test may exhibit interference when sample is collected from a person who is consuming a supplement with a high dose of biotin (also termed as vitamin B7 or B8, vitamin H, or coenzyme R). It is recommended to ask all patients who may be indicated for this test about biotin supplementation. Patients should be cautioned to stop biotin consumption at least 72 hours prior to the collection of a sample.

Expected Turnaround Time

4 - 5 days

Turnaround time is defined as the usual number of days from the date of pickup of a specimen for testing to when the result is released to the ordering provider. In some cases, additional time should be allowed for additional confirmatory or additional reflex tests. Testing schedules may vary.

Related Documents

Specimen Requirements

Specimen

Serum

Volume

1 mL

Minimum Volume

0.5 mL (Note: This volume does not allow for repeat testing.)

Container

Red-top tube or gel-barrier tube

Collection

If a red-top tube is used, transfer separated serum to a plastic transport tube.

Storage Instructions

Room temperature; stable at room temperature or refrigerated for 14 days.

Patient Preparation

It is suggested that the assay not be performed until at least three weeks after the completion of primary chemotherapy and at least two months following abdominal surgery.

Causes for Rejection

Citrate plasma specimen; improper labeling

Test Details

Use

Eliminate interference from HAMA in the CA 125 assay to help monitor disease progression in nonmucinous epithelial neoplasms of the ovary. This test is performed in the same way as the Cancer Antigen (CA) 125 test except that the interference from HAMA present in the specimen is eliminated by use of a blocking reagent.

Limitations

CA 125 is not specific for tumors of the ovary and cannot distinguish benign from malignant tumors. It is not a screening test.

Methodology

Electrochemiluminescence immunoassay (ECLIA)

Reference Interval

• Female: 0.0−38.1 units/mL

• Male: Not established

LOINC® Map

Order Code Order Code Name Order Loinc Result Code Result Code Name UofM Result LOINC
144733 CA 125 in the Presence of HAMA 10334-1 144738 CA 125 in the Presence of HAMA U/mL 10334-1

For Providers

Please login to order a test

Order a Test

© 2021 Laboratory Corporation of America® Holdings and Lexi-Comp Inc. All Rights Reserved.

CPT Statement/Profile Statement

The LOINC® codes are copyright © 1994-2021, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. Permission is granted in perpetuity, without payment of license fees or royalties, to use, copy, or distribute the LOINC® codes for any commercial or non-commercial purpose, subject to the terms under the license agreement found at https://loinc.org/license/. Additional information regarding LOINC® codes can be found at LOINC.org, including the LOINC Manual, which can be downloaded at LOINC.org/downloads/files/LOINCManual.pdf